The DCA indicated that the net clinical benefit of merge_SVM was higher than that of DBT_SVM and US_SVM, indicating that the fusion model has higher clinical applicability and can provide a non-invasive prediction method for Ki-67 level in breast cancer. This evidence concerns the gene MKI67 and breast carcinoma.